Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 Life Science Investing
Rain Enhancement Technologies' Upper Yampa Weather Enhancement Pilot Advances Toward Final Permit Approval After Colorado Public Hearing Life Science Investing
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule Biotech Investing
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies Life Science Investing
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer Life Science Investing
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto Life Science Investing
Agility Robotics Expands Pittsburgh Presence to Support Growing Customer Deployments Life Science Investing
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Life Science Investing
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Life Science Investing
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
